123 related articles for article (PubMed ID: 24074918)
1. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
Herman JM; Fan KY; Wild AT; Wood LD; Blackford AL; Donehower RC; Hidalgo M; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):458-9. PubMed ID: 24074918
[No Abstract] [Full Text] [Related]
2. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
Herman JM; Jabbour SK; Lin SH; Deek MP; Hsu CC; Fishman EK; Kim S; Cameron JL; Chekmareva M; Laheru DA; Narang AK; Pawlik TM; Hruban RH; Wolfgang CL; Iacobuzio-Donahue CA
Pancreas; 2018 Feb; 47(2):208-212. PubMed ID: 29329157
[TBL] [Abstract][Full Text] [Related]
3. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
[TBL] [Abstract][Full Text] [Related]
4. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
[TBL] [Abstract][Full Text] [Related]
5. Can we move towards personalised pancreatic cancer therapy?
Jamieson NB; Chang DK; Grimmond SM; Biankin AV
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):335-8. PubMed ID: 24702631
[No Abstract] [Full Text] [Related]
6. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
[TBL] [Abstract][Full Text] [Related]
7. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Takahashi H; Akita H; Gotoh K; Kobayashi S; Marubashi S; Miyoshi N; Sugimura K; Motoori M; Kishi K; Noura S; Fujiwara Y; Ohue M; Ohigashi H; Yano M; Sakon M; Ishikawa O
Surgery; 2015 Mar; 157(3):484-95. PubMed ID: 25444512
[TBL] [Abstract][Full Text] [Related]
8. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
[TBL] [Abstract][Full Text] [Related]
9. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
10. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
[TBL] [Abstract][Full Text] [Related]
11. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Kinnier CV; Ferrone CR
Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
[No Abstract] [Full Text] [Related]
13. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
Singh P; Wig JD; Srinivasan R; Radotra BD
Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
[TBL] [Abstract][Full Text] [Related]
14. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
17. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
Singh P; Srinivasan R; Wig JD
Pancreas; 2012 May; 41(4):541-6. PubMed ID: 22504380
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
19. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.
Paiella S; Malleo G; Cataldo I; Gasparini C; De Pastena M; De Marchi G; Marchegiani G; Rusev B; Scarpa A; Girelli R; Giardino A; Frigerio I; D'Onofrio M; Secchettin E; Bassi C; Salvia R
Langenbecks Arch Surg; 2018 Mar; 403(2):213-220. PubMed ID: 28983662
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in pancreatic cancer.
Jones OP; Melling JD; Ghaneh P
World J Gastroenterol; 2014 Oct; 20(40):14733-46. PubMed ID: 25356036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]